Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- PDA Closure Set from Japan Lifeline Recommended for Approval
December 15, 2008
- Chugai, Chiome Sign Agreement on Monoclonal Antibody Production
December 15, 2008
- SELF-MEDICATION NEWS IN BRIEF
December 15, 2008
- BUSINESS NEWS IN BRIEF
December 15, 2008
- SURVEY／Diabetes Is Most Commonly Examined
December 15, 2008
- Wholesalers Should Talk with Manufacturers on Equal Footing: Mr Negi
December 15, 2008
- JSMO to Prepare GL for KRAS Gene Mutation Testing
December 15, 2008
- Sales Up, Profits Down for Generic Companies as a Whole in FY2007
December 15, 2008
- Appropriate Diagnosis of Sleep Disorders by Specialists Necessary: NBI Seminar
December 15, 2008
- Over 40% of Pharmacists Unsatisfied with Generic Houses' Call Center Services
December 15, 2008
- Opinions Divided within LDP on Tobacco Tax
December 15, 2008
- Earlier Approval Is More Important than Risk of Problems due to Ethnic Differences
December 15, 2008
- NHI Pricing Recommended for Approval for 9 APIs
December 15, 2008
- Precautions Needed for Infections in Treating RA with Actemra: PMS Data
December 15, 2008
- 2 Combinations of ARB and Diuretic Recommended for Approval
December 15, 2008
- Gov't to Relax Belt-Tightening Fiscal Policy
December 15, 2008
- REGULATORY NEWS IN BRIEF
December 15, 2008
- Research on Biomarkers Essential to Develop Anticancer Drugs: Dr Inoue
December 15, 2008
- Pfizer to Break Dependence on Blockbusters: Mr Iwasaki
December 15, 2008
- Tripartite Collaboration Needed to Bring Benefits of iPS Cells to Patients: Prof. Yamanaka
December 15, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…